Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | RAF1 | P04049 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775880 | 0.92 | RPS6KA3 (0.35) | RPS6KA2KMOFAAHRPS6KA3 | |
| SCHEMBL16775870 | 0.87 | GRM5 (0.39) | CA9RPS6KA2KMOADORA3ADORA2A | |
| SCHEMBL16775871 | 0.81 | EGFR (0.33) | RPS6KA2KDRRAF1CYP3A4KMO | |
| SCHEMBL16785536 | 0.80 | RAF1 (0.36) | CA9RAF1KMOADORA2A | |
| SCHEMBL16776144 | 0.79 | KMT2A (0.44) | CA9RPS6KA2KMOFAAHALDH1A1 | |
| SCHEMBL16775872 | 0.79 | PIK3CA (0.33) | KMOFAAHRPS6KA3 | |
| SCHEMBL18415694 | 0.78 | RAF1 (0.38) | KDRRAF1 | |
| SCHEMBL16785561 | 0.78 | FGFR4 (0.36) | CA9RAF1KMO | |
| SCHEMBL16775855 | 0.76 | CA9 (0.39) | CA9RPS6KA2KDRCYP1A2CYP3A4 | |
| SCHEMBL16775921 | 0.76 | FGFR4 (0.37) | CA9RPS6KA2KMOADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA9 4248/4885RPS6KA2 2318/4885KDR 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.